Thus, it is quite possible that the remaining 55 failures in the MOTIVATE trials might relate to sensitivity of the infecting virus to MVC prior to treatment or simply, the inability to detect MVC resistance at the time of treatment failure with existing assays.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}